This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints, Permissions and Rights Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Siddiqi, A. Articles by Burrin, J. M. Search for Related Content PubMed PubMed Citation Articles by Siddiqi, A. Articles by Burrin, J. M.

Serum Cytokines in Thyrotoxicosis¹

Departments of Clinical Biochemistry (A.S., J.M.B.) and Endocrinology (A.S., J.P.M., D.F.W., G.M.B., J.M.B.), St. Bartholomew’s and Royal London School of Medicine and Dentistry, London E1 1BB, United Kingdom

Address all correspondence and requests for reprints to: Dr. Ayesha Siddiqi, Medical Unit, Alexandra Wing, Royal London Hospital, Whitechapel, London E1 1BB, United Kingdom. E-mail: a.siddiqi{at}mds.qmw.ac.uk

Overproduction of thyroid hormones promotes bone resorption in vivo and in vitro, and we have evaluated whether mediators of such effects could include the osteotropic cytokines. Previous studies have demonstrated raised serum interleukin (IL)-6 in thyrotoxic patients, but differentiating the contribution of the elevated thyroid hormones from that of the autoimmune inflammation present in Graves’ disease (GD) has been difficult. We undertook a longitudinal study of 34 patients (19–45 yr old) with GD, toxic nodular goiter (TNG), or a history of thyroid carcinoma but no evidence of disease recurrence, receiving sufficient T₄ to suppress TSH. Controls were 12 euthyroid females. The following measurements were made basally and for 6 months after carbimazole treatment: serum free T₄, T₃, bone-specific alkaline phosphatase (b-ALP), IL-6, IL-8, IL-1ß, tumor necrosis factor-, IL-11, and urinary deoxypyridinoline (Udpd). Compared with controls (IL-6, 1.1 ± 0.3 ng/L; IL-8, 3.2 ± 0.8 ng/L), untreated patients with GD and TNG had elevated IL-6 (GD, 7.11 ± 0.88 ng/L; TNG, 7.30 ± 0.77 ng/L; P < 0.001) and IL-8 (GD, 10.3 ± 1.23 ng/L; TNG, 9.81 ± 1.27 ng/L; P < 0.001). These levels fell after treatment and were then indistinguishable from those in control subjects. Thyroid carcinoma patients on TSH suppressive therapy also had significantly raised levels of IL-6 (2.5 ± 0.42 ng/L) and IL-8 (4.4 ± 0.63 ng/L). When data from all the patients were pooled, the levels of IL-6 and IL-8 correlated with serum T₃ and free T₄ but not with Udpd or b-ALP. IL-1ß, IL-11, and tumor necrosis factor- were not raised in any patient.

The elevations in serum IL-6 and -8 that occur in hyperthyroidism seem to result from the chronic effects of thyroid hormone excess rather than the accompanying autoimmune inflammatory condition produced by Graves’ thyroid or eye disease. The site of the presumed increased production of IL-6 and -8 is most likely from bone osteoblasts, despite the inability of bone markers (such as Udpd and b-ALP) to correlate with acute changes in thyroid hormone status produced by antithyroid therapy.

This article has been cited by other articles:

				A. Antonelli, M. Rotondi, P. Fallahi, M. Grosso, G. Boni, S. M. Ferrari, P. Romagnani, M. Serio, G. Mariani, and E. Ferrannini Iodine-131 Given for Therapeutic Purposes Modulates Differently Interferon-{gamma}-Inducible {alpha}-Chemokine CXCL10 Serum Levels in Patients with Active Graves' Disease or Toxic Nodular Goiter J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1485 - 1490. [Abstract] [Full Text] [PDF]

				A. Antonelli, P. Fallahi, M. Rotondi, S. M. Ferrari, P. Romagnani, M. Grosso, E. Ferrannini, and M. Serio Increased serum CXCL10 in Graves' disease or autoimmune thyroiditis is not associated with hyper- or hypothyroidism per se, but is specifically sustained by the autoimmune, inflammatory process. Eur. J. Endocrinol., May 1, 2006; 154(5): 651 - 658. [Abstract] [Full Text] [PDF]

				A. L. D. Riis, T. K. Hansen, S. Thiel, C. H. Gravholt, S. Gjedde, L. C. Gormsen, J. O. L. Jorgensen, J. Weeke, and N. Moller Thyroid hormone increases mannan-binding lectin levels Eur. J. Endocrinol., November 1, 2005; 153(5): 643 - 649. [Abstract] [Full Text] [PDF]

				J. I Botella-Carretero, A. Prados, L. Manzano, M. T Montero, L. Escribano, J. Sancho, and H. F Escobar-Morreale The effects of thyroid hormones on circulating markers of cell-mediated immune response, as studied in patients with differentiated thyroid carcinoma before and during thyroxine withdrawal Eur. J. Endocrinol., August 1, 2005; 153(2): 223 - 230. [Abstract] [Full Text] [PDF]

				A. Siddiqi, M. P. Parsons, J. L. Lewis, J. P. Monson, G. R. Williams, and J. M. Burrin TR Expression and Function in Human Bone Marrow Stromal and Osteoblast-Like Cells J. Clin. Endocrinol. Metab., February 1, 2002; 87(2): 906 - 914. [Abstract] [Full Text] [PDF]

				C. J. Auernhammer and S. Melmed Leukemia-Inhibitory Factor--Neuroimmune Modulator of Endocrine Function Endocr. Rev., June 1, 2000; 21(3): 313 - 345. [Abstract] [Full Text]

				B. M. Jones, C. C. H. Kwok, and A. W. C. Kung Effect of Radioactive Iodine Therapy on Cytokine Production in Graves' Disease: Transient Increases in Interleukin-4 (IL-4), IL-6, IL-10, and Tumor Necrosis Factor-{alpha}, with Longer Term Increases in Interferon-{gamma} Production J. Clin. Endocrinol. Metab., November 1, 1999; 84(11): 4106 - 4110. [Abstract] [Full Text]